Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports -- Nature, of collaborative studies with Duke ...

A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

The MarketWatch News Department was not involved in the creation of this content. RALEIGH, N.C., Feb. 17, 2026 /PRNewswire/ -- Accord Healthcare, Inc., a leading U.S. pharmaceutical company, today ...

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant ...

May 10, 2012 — Lenalidomide (Revlimid) combined with dexamethasone has proven to be an effective treatment for patients with newly diagnosed or relapsed/refractory multiple myeloma. Three new studies, ...

Phase I data presented at the 2023 American Society of Hematology (ASH) annual meeting showed the benefit of lenalidomide (Revlimid) rechallenge in relapsed/refractory multiple myeloma patients ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study GMMG-HD7 is an open-label, randomized, multicenter, ...

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM ...

Lenalidomide, a derivative of thalidomide, is a FDA-approved drug for the treatment of multiple myeloma (MM). Recent clinical studies have extended the therapeutic effectiveness of lenalidomide ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of lenalidomide, having considered evidence on the nature of low‑ or intermediate‑1 risk myelodysplastic ...

Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish the maximum tolerated dose of ...